SAN DIEGO, April 23 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today announced that it has added two key people to its management team. Maurice Mezzino has been hired to the position of vice president, chief business officer, and Andrea Loewen-Rodriguez joins the company as senior director, regulatory affairs. These positions have been created to support development and commercial activities as Ceregene transitions to a later stage biotechnology company with two product candidates in clinical trials -- CERE-110 for Alzheimer's disease and CERE-120 for Parkinson's disease.
"We are excited to add two such experienced professionals to our leadership team during a time when we are advancing our product candidates into late-stage clinical development, with CERE-120 for Parkinson's disease potentially entering Phase 3 clinical trials next year," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer. "Maurice will be a key contributor toward our business and partnering strategies having structured and completed multiple deals during his career, and Andrea will play an important role in liaising with the FDA and European regulators in our efforts to move our therapies through the approval process."
Maurice Mezzino, a business development executive with more than 20
years of biopharmaceutical industry experience, joins us from Biogen Idec,
where he has been since 2000, serving most recently as vice president,
business development, responsible for managing the west coast business
development team. Among his accomplishments, Mr. Mezzino spearheaded an
oncology strategic alliance between IDEC and Biogen in 2003, which was a
precursor to the merger between the companies later that year; and in 2006
he led the acquisition of Conforma Therapeutics. Prior to Biogen Idec, Mr.
Mezzino held a variety of positions in clinical development, business
planning, strategic marketing and business development at Bristol-Myers
|SOURCE Ceregene, Inc.|
Copyright©2008 PR Newswire.
All rights reserved